SCHEMBL4706433

SCHEMBL4706433

COCC(=O)Nc1cccc(C(=O)C(=O)c2ccncc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
MAPT P10636 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 6/20 0.50
KDM5A P29375 1/20 0.49
KDM4D Q6B0I6 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
KDM5B Q9UGL1 1/20 0.49
KDM2A Q9Y2K7 1/20 0.49
KDM3A Q9Y4C1 1/20 0.49
KCNK3 O14649 2/20 0.49
HPGD P15428 2/20 0.49
CYP2C19 P33261 1/20 0.49
ALOX12 P18054 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
TSHR P16473 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8228787 0.81 CYP2C19 (0.67) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL9495103 0.80 SMN1; SMN2 (0.71) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL3458300 0.79 ALDH1A1 (0.55) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL4705977 0.78 SMN1; SMN2 (0.52) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL6081279 0.75 SMN1; SMN2 (0.58) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL6579498 0.74 MAPK1 (0.68) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL11412031 0.74 SMN1; SMN2 (0.64) MAPTSMN1; SMN2ALDH1A1KDM4CHPGD
SCHEMBL7879000 0.73 SMN1; SMN2 (0.47) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL2800153 0.73 ALDH1A1 (0.73) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL11680494 0.73 SMN1; SMN2 (0.62) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966185-A2 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION Wyeth a Corporation of the State of Delaware (US) 2008-09-10 EP disclosed
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation WYETH (US) 2007-08-16 US disclosed
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation WYETH (US) 2007-08-16 US disclosed
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation WYETH (US) 2007-08-16 US disclosed
WO-2007078813-A2 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION WYETH (US) 2007-07-12 WO disclosed
WO-2007078813-A2 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION WYETH (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation BACE1, BACE2, PSEN1 KMT2A 2428/4885MEN1 4385/4885MAPT 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.